Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
afatinib + tetracycline
- Development stage
- Phase 2
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy approach where tetracycline antibiotics are used prophylactically or concurrently with afatinib to manage skin toxicities, particularly acneiform rash, associated with afatinib treatment in non-small cell lung cancer (NSCLC) patients. Afatinib is a second-generation, irreversible ErbB-family blocker that covalently binds to and blocks signaling from EGFR, HER2, ErbB3, and ErbB4, while tetracyclines are used to prevent or reduce the severity of skin reactions, which are common adverse effects of EGFR inhibitors.
02
Targets
EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB3 (Erb-b2 receptor tyrosine kinase 3)ERBB4 (Erb-b2 receptor tyrosine kinase 4)TRIB2
Beyond the preview
Go deeper on afatinib + tetracycline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on afatinib + tetracycline.